Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CNC NYSE:NAVB NASDAQ:OCDX NYSE:VNRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNCCentene$32.66-1.8%$28.74$25.08▼$77.29$16.04B0.449.24 million shs11.51 million shsNAVBNavidea Biopharmaceuticals$0.00$0.00$0.00▼$0.13$50K1.997,258 shs1,404 shsOCDXOrtho Clinical Diagnostics$17.63$17.63$16.04▼$22.99$3.92B1.321.24 million shs5,400 shsVNRXVolitionRx$0.63-3.9%$0.67$0.40▼$0.94$67.81M1.27198,056 shs135,733 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNCCentene0.00%+14.62%+16.49%-39.26%-55.94%NAVBNavidea Biopharmaceuticals0.00%0.00%0.00%-28.57%-50.00%OCDXOrtho Clinical Diagnostics0.00%0.00%0.00%0.00%0.00%VNRXVolitionRx0.00%+8.99%-5.58%-8.25%-3.46%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNCCentene$32.66-1.8%$28.74$25.08▼$77.29$16.04B0.449.24 million shs11.51 million shsNAVBNavidea Biopharmaceuticals$0.00$0.00$0.00▼$0.13$50K1.997,258 shs1,404 shsOCDXOrtho Clinical Diagnostics$17.63$17.63$16.04▼$22.99$3.92B1.321.24 million shs5,400 shsVNRXVolitionRx$0.63-3.9%$0.67$0.40▼$0.94$67.81M1.27198,056 shs135,733 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNCCentene0.00%+14.62%+16.49%-39.26%-55.94%NAVBNavidea Biopharmaceuticals0.00%0.00%0.00%-28.57%-50.00%OCDXOrtho Clinical Diagnostics0.00%0.00%0.00%0.00%0.00%VNRXVolitionRx0.00%+8.99%-5.58%-8.25%-3.46%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNCCentene 2.12Hold$38.3317.37% UpsideNAVBNavidea Biopharmaceuticals 0.00N/AN/AN/AOCDXOrtho Clinical Diagnostics 0.00N/AN/AN/AVNRXVolitionRx 3.00Buy$3.50455.38% UpsideCurrent Analyst Ratings BreakdownLatest OCDX, VNRX, NAVB, and CNC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025CNCCenteneBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$33.00 ➝ $35.009/12/2025CNCCenteneTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$35.00 ➝ $39.009/10/2025VNRXVolitionRxD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.009/5/2025CNCCenteneSanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$40.00 ➝ $36.009/4/2025CNCCenteneBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetEqual Weight$45.00 ➝ $33.008/26/2025CNCCenteneCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$38.008/15/2025VNRXVolitionRxD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.008/4/2025CNCCenteneMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$33.00 ➝ $28.007/29/2025CNCCenteneJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$48.00 ➝ $30.007/28/2025CNCCenteneCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral$65.00 ➝ $38.007/28/2025CNCCenteneUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$45.00 ➝ $31.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNCCentene$178.19B0.09$9.72 per share3.36$52.49 per share0.62NAVBNavidea Biopharmaceuticals$8.13K6.16N/AN/AN/A∞OCDXOrtho Clinical Diagnostics$2.04B1.92$2.28 per share7.73$1.99 per share8.86VNRXVolitionRx$1.32M51.40N/AN/A($0.11) per share-5.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNCCentene$3.31B$4.048.084.431.351.15%9.57%3.10%10/24/2025 (Estimated)NAVBNavidea Biopharmaceuticals-$15.18MN/A0.00∞N/AN/AN/AN/AN/AOCDXOrtho Clinical Diagnostics-$54.30M-$0.01N/A17.631.66-0.02%41.71%5.10%N/AVNRXVolitionRx-$35.32M-$0.25N/A∞N/A-2,321.14%N/A-163.39%N/ALatest OCDX, VNRX, NAVB, and CNC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/25/2025Q2 2025CNCCentene$0.23-$0.16-$0.39-$0.51$44.71 billion$48.74 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNCCenteneN/AN/AN/AN/AN/ANAVBNavidea BiopharmaceuticalsN/AN/AN/AN/AN/AOCDXOrtho Clinical DiagnosticsN/AN/AN/AN/AN/AVNRXVolitionRxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNCCentene0.641.101.10NAVBNavidea BiopharmaceuticalsN/AN/AN/AOCDXOrtho Clinical Diagnostics4.911.891.29VNRXVolitionRxN/A0.220.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNCCentene93.63%NAVBNavidea Biopharmaceuticals0.01%OCDXOrtho Clinical DiagnosticsN/AVNRXVolitionRx8.09%Insider OwnershipCompanyInsider OwnershipCNCCentene0.36%NAVBNavidea Biopharmaceuticals43.68%OCDXOrtho Clinical DiagnosticsN/AVNRXVolitionRx10.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNCCentene60,500491.13 million489.37 millionOptionableNAVBNavidea Biopharmaceuticals10100.08 million56.37 millionOptionableOCDXOrtho Clinical Diagnostics4,800222.59 millionN/ANot OptionableVNRXVolitionRx80107.60 million80.80 millionOptionableOCDX, VNRX, NAVB, and CNC HeadlinesRecent News About These CompaniesD. Boral Capital Reiterates "Buy" Rating for VolitionRx (NYSE:VNRX)September 12 at 8:19 AM | marketbeat.comVolitionRx signs first human out licensing deal for APSSeptember 9, 2025 | msn.comVolition Signs First Human Out Licensing DealSeptember 9, 2025 | prnewswire.comZacks Small Cap Estimates VolitionRx Q3 EarningsAugust 29, 2025 | marketbeat.comQ3 Earnings Forecast for VolitionRx Issued By HC WainwrightAugust 22, 2025 | marketbeat.comHC Wainwright Has Negative Outlook of VolitionRx Q4 EarningsAugust 21, 2025 | marketbeat.comVolitionRx Limited (AMEX:VNRX) Q2 2025 Earnings Call TranscriptAugust 16, 2025 | msn.comVolitionRx Limited (VNRX) Q2 2025 Earnings Call TranscriptAugust 15, 2025 | seekingalpha.comVolitionRx reports Q2 revenue $400K, consensus $375.72KAugust 14, 2025 | msn.comVolitionRx Limited Announces Second Quarter 2025 Financial Results and Business UpdateAugust 14, 2025 | prnewswire.comInsights into VolitionRX's Upcoming EarningsAugust 14, 2025 | benzinga.comVolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update | ...August 8, 2025 | gurufocus.comVolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business UpdateAugust 8, 2025 | prnewswire.comVolitionRx Limited (NYSE:VNRX) Director Acquires $50,000.00 in StockAugust 7, 2025 | insidertrades.comVolitionRx Announces Pricing of $1.2 Million Registered Direct OfferingAugust 4, 2025 | prnewswire.comNu.Q® Discover Expands Global Adoption and Epigenetic InnovationJuly 16, 2025 | prnewswire.comVolitionRx Limited (VNRX) - Yahoo FinanceJuly 11, 2025 | nz.finance.yahoo.comVolition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of NucleosomesJuly 8, 2025 | prnewswire.comVolition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ FailureJune 12, 2025 | prnewswire.comJones Trading Initiates Coverage of VolitionRx (VNRX) with Buy RecommendationJune 11, 2025 | msn.comVolitionRx director Guy Innes buys $10,772 in common stockJune 5, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOCDX, VNRX, NAVB, and CNC Company DescriptionsCentene NYSE:CNC$32.66 -0.60 (-1.80%) Closing price 03:59 PM EasternExtended Trading$32.49 -0.16 (-0.51%) As of 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children's health insurance program, foster care, medicare-medicaid plans, long-term services and support. This segment also provides healthcare products. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual, small, and large group commercials. It also operates clinical healthcare and pharmacies, as well as offers dental and speech therapy services. In addition, the company engages in the government contracts business under the TRICARE program and other healthcare related government contracts. It provides services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in Saint Louis, Missouri.Navidea Biopharmaceuticals NYSE:NAVB$0.0005 0.00 (0.00%) As of 03:55 PM EasternNavidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.Ortho Clinical Diagnostics NASDAQ:OCDXOrtho Clinical Diagnostics Holdings plc provides in-vitro diagnostics solutions to the clinical laboratory and transfusion medicine communities worldwide. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases. The company is also involved in the provision of contract manufacturing and orthocare services. Its products are used in hospitals, laboratories, clinics, blood banks, and donor centers. Ortho Clinical Diagnostics Holdings plc was founded in 1939 and is headquartered in Raritan, New Jersey.VolitionRx NYSE:VNRX$0.63 -0.03 (-3.83%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
